(Bloomberg) -- Two former Theranos directors said they didn’t think toquestion executives as allegations arose that the strugglingstartup used existing blood-testing technology rather than itsheralded system to analyze samples.

Former U.S. Secretary of State George Shultz and retired U.S.Navy Admiral Gary Roughead, who served on Theranos’ boardacknowledged that they failed to confront Chief Executive Elizabeth Holmes about theallegations because they believed her claims about the technology’scapabilities, according to court documents unsealed May 26 inDelaware.

“That’s what I assumed,” Shultz testified under oath April 4. “Ididn’t probe into it. It didn’t occur to me.”

Continue Reading for Free

Register and gain access to:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Consumer Driven Health Care
C-Suite
Legal